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from both the parents’/patients’ and clinicians’ perspectives to help guide research and clinical
efforts to improve the lives of people with bronchiectasis https://bit.ly/3xoonwi
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Abstract
The global burden of children and young people (CYP) with bronchiectasis is being recognised
increasingly. They experience a poor quality of life and recurrent respiratory exacerbations requiring
additional treatment, including hospitalisation. However, there are no published data on patient-driven
clinical needs and/or research priorities for paediatric bronchiectasis.
Parent/patient-driven views are required to understand the clinical needs and research priorities to inform
changes that benefit CYP with bronchiectasis and reduce their disease burden. The European Lung
Foundation and the European Respiratory Society Task Force for paediatric bronchiectasis created an
international roadmap of clinical and research priorities to guide, and as an extension of, the clinical
practice guideline.
This roadmap was based on two global web-based surveys. The first survey (10 languages) was completed
by 225 respondents (parents of CYP with bronchiectasis and adults with bronchiectasis diagnosed in
childhood) from 21 countries. The parent/patient survey encompassed both clinical and research priorities.
The second survey, completed by 258 health practitioners from 54 countries, was limited to research
priorities.
The two highest clinical needs expressed by parents/patients were: having an action management plan for
flare-ups/exacerbations and access to physiotherapists. The two highest health practitioners’ research
priorities related to eradication of airway pathogens and optimal airway clearance techniques. Based on
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both surveys, the top 10 research priorities were derived, and unanimous consensus statements were
formulated from these priorities.
This document addresses parents’/patients’ clinical and research priorities from both the parents’/patients’
and clinicians’ perspectives and will help guide research and clinical efforts to improve the lives of people
with bronchiectasis.
Introduction
Bronchiectasis unrelated to cystic fibrosis (CF) is no longer considered rare [1–3] and is associated with a
high disease burden for children and young people (CYP) as well as in adults, their families and health
systems, resulting in substantial economic costs [4, 5]. Nevertheless, substantial knowledge gaps exist, and
while there are published research priorities for adults with bronchiectasis [6, 7], research priorities
considered important by parents of children with bronchiectasis and the clinical needs of people with
bronchiectasis are unknown.
Paediatric-specific data are important, as although bronchiectasis in CYP and adults share some clinical
similarities (e.g. wet/productive cough and superimposed exacerbations [4]), there are substantial disparities
in several key areas. CYP require developmental-appropriate parental care and support. Important
biological differences include altered pathogen profiles (bacteria [8] and microbiota [9]), age-related
immunological responses [10] and treatment outcomes [1]. Diagnostic [1] and treatment methods, such as
airway clearance techniques (ACTs), may also differ according to age [11, 12]. Additionally, comorbidities
and underlying aetiologies are substantially different between adults and children [4]. Finally, while
bronchiectasis was once thought irreversible and progressive, disease progression in children with mild
disease can be halted and sometimes even reversed with optimal clinical management [1].
To address the lack of published research priorities and patient-derived “needs assessment” data for CYP
with bronchiectasis, we undertook this project as an extension of the European Respiratory Society (ERS)
clinical practice guideline (CPG) for managing children and adolescents with bronchiectasis [12]. We
sought to develop a roadmap to guide health services and research priorities pertinent to the needs of CYP
(and their parents/carers) with bronchiectasis, in order to reduce their disease burden and improve their
short- and long-term outcomes.
Methods
The European Lung Foundation (ELF) led two web-based surveys with the working group as detailed in
the supplementary material. The first involved parents of CYP with bronchiectasis and adults with
bronchiectasis as a child (henceforth called parents/patients group) and focused on priorities relating to
parent/patient-based clinical needs and research. The second survey involved health practitioners focused
on research priorities only (figure 1).
Parent/patient survey on quality of life, clinical needs and research priorities
Survey questions were formulated in English by the working group and consisted of de novo questions
(from clinical experience) in addition to those adapted from the adult-based documents from the ERS [6]
and United States [7]. The survey was professionally translated into nine languages and distributed widely
(SurveyMonkey platform) between July 2019 and January 2020. It consisted of: 1) demographics;
2) effects of items on the child’s and respondent’s quality of life (QoL); and 3) other questions referring to
clinical and research priorities, framed around “concerns about your child’s/your health”. For each
non-demographic question, there were four possible answers: 1=no effect, 2=minor, 3=moderate and
4=major effect.
The working group grouped the summarised participants’ priorities into research and/or clinical entities
and categorised them into themes. The results, groupings and themes were reiteratively discussed with the
two parent advisory groups (PAG): CPG and an Australian-based PAG.
Health practitioner survey for research priorities
The 49 items for the health practitioners survey were generated by the working group based on: 1) research
questions raised from our CPG [12]; and 2) items adapted from adult data [6, 7]. After several reiterations
among the working group members, the link to the web-based survey (only in English) was sent to
members of the ERS paediatrics assembly. Working group members also sent the link to non-Europeans/
ERS collaborators. The survey was open between 28 July 2020 and 30 September 2020 and utilised a
five-point scale (1=unimportant, 2=slightly important, 3=moderately important, 4=very important,
5=essential). As with the parent/patient survey, the working group then grouped the priorities into research
themes, matching the parent/patient-based themes.
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Selection of the top 10 research priorities and formulating consensus statements
Research priorities from both surveys were collated, condensed and summarised to identify the top 10
priorities. We did not rank them but planned a voting process if consensus (PAG and working group)
could not be obtained. The top 10 priorities were also reviewed by the Australian-based PAG (https://
crelungs.org.au/cre-parent-and-community-advisory-group). Consensus statements were then formulated by
the working group based on these research priorities.
Results
Parent/patient survey
Overall, 225 participated; 70 (31%) were adults with bronchiectasis diagnosed during childhood and 155
(69%) parents/carers of a CYP with bronchiectasis. Seven items rated by parents affecting their child’s
QoL (figure 2a) had mean scores >3; the top five items related to physiotherapy/airway clearance,
medications, exacerbations, disease and symptoms management, and cough. Aspects most affecting the
parent’s own QoL were dedicated time for disease management, obtaining medical assistance and
preventing infection (figure 2b).
The mean item scores for clinical needs and research priorities are presented in tables 1 and 2, respectively.
The three highest clinical needs were “Having an action management plan for flare-ups/exacerbations”,
“Having access to physiotherapy and being taught the techniques and how to use the equipment at home”
and “Good communication between healthcare professionals and each person with bronchiectasis” (table 1).
The three highest rated research priorities (table 2) were “Identifying what makes some patients’
bronchiectasis get worse”, “Finding ways to prevent bronchiectasis” and “Identifying how bronchiectasis
develops and continues”.
Health practitioner survey
The mean scores of the 258 health practitioners (from 54 countries) were 3.19–4.41 with little variation
between practitioners grouped by number of patients with bronchiectasis seen regularly in their clinics
Survey questions based on panelʹs
clinical practice and documented ERS 
and United States of America priorities 
from adults with bronchiectasis
Survey questions based on ERS 
paediatric clinical practice guidelines 
and documented ERS and United States 
of America priorities from adults 
with bronchiectasis
Survey undertaken by ERS Paediatric 
Assembly members and other worldwide 
experts in bronchiectasis
Data summarised by ELF
Reviewed by parent advisory groups with working group
Consensus statements based on the top 10 research priorities
Items categorised by the working group
Data summarised by ELF
Panel and parents
Electronic version (in 10 languages)
of refined questions sent out by ELF
Items categorised by the working group
Health practitioners'





Reviewed by ELF parent 
advisory group
FIGURE 1 Overview of the project methodology. ELF: European Lung Foundation; ERS: European Respiratory
Society.
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(supplementary figure S1). Of the top six items (two items ranked equal 5th), four related to antibiotics
(table 3), one to airway clearance and the other to factors associated with rapid progression and poor
outcomes. Supplementary table S1 ranks items by mean scores.
FIGURE 2 Results from the parent/patient survey relating to aspects of their child’s bronchiectasis on their quality of life. a) Mean scores of items
rated by parents affecting their child’s quality of life. b) Mean scores of items rated by parents affecting their own quality of life. #: e.g. walking far,
swimming.
TABLE 1 Parent/patient survey: clinical needs themes and priorities
Theme Items (verbatim from survey questions) Mean
score
Awareness and diagnosis To find ways to diagnose bronchiectasis earlier, such as by local doctors# 3.86
To improve awareness of bronchiectasis in community care services, e.g. among community-based
nurses and physiotherapists
3.82
To identify the cause(s) of bronchiectasis 3.80
Education and support for
parents and families
Knowing more about the role of physiotherapy and pulmonary rehabilitation (a short course of
regular exercise sessions and education sessions)
3.80
Having access to reliable, easy to understand information about different aspects of living with
bronchiectasis
3.78
Providing each person with copies of their test results so they can keep a useful history of the
progress of their own condition
3.74
Develop better ways of teaching people to use their medicines 3.71
Improving access to quality care Having access to physiotherapy and being taught the techniques and how to use the equipment
at home
3.94
Good communication between healthcare professionals and each person with bronchiectasis 3.91
Testing new techniques for managing bronchiectasis in real world environments, such as at home
and community
3.86
Better access to tests and experts on bronchiectasis 3.80
Using peer support forums and social media to exchange information with others 3.52
Managing exacerbations Having an action management plan for flare-ups/exacerbations 3.94
Having a self-management programme and care plan designed with each person to help them
have greater control over their condition and recognise/manage an exacerbation
3.92
Finding triggers of exacerbation 3.86
Educating primary care doctors to prescribe the same dose/length of antibiotic therapy for
exacerbations as used in cystic fibrosis¶
3.81
Improving treatment To improve how children with bronchiectasis are treated through using longer-term antibiotic
therapy when a person’s condition is stable+
3.71
Being able to identify people at increased risk of poor outcomes or needing urgent treatment for
their bronchiectasis
3.85
Being able to monitor and treat the coughing up of blood 3.77
Improving monitoring Having regular lung function testing to help notice changes or increased risk of an exacerbation 3.76
Being able to monitor cough 3.68
Regular sputum examinations when a person is stable and during an exacerbation to learn more
about how the condition changes
3.64
Having the equipment at home to monitor symptoms 3.58
Ensuring each person has access to a home intravenous antibiotic service to avoid unnecessary
hospital admissions
3.53
Having regular computed tomography scans to look for changes or increased risk of an
exacerbation§
3.45
#: refers to parent’s/patient’s experience of delayed referral from a lack of awareness of the symptoms of bronchiectasis and dismissing children’s
chronic wet cough; importantly, we do not expect primary care doctors to undertake computed tomography (CT) scans in young children. ¶: refers
to parent’s/patient’s experience that they are often given a shorter antibiotic course (e.g. 3 days as opposed to current guideline recommendations
of 14 days [12]) and/or lower doses than what is generally considered optimal; doses for children with CF are generally higher than for those
without CF as children with CF have higher volume of distribution and renal clearance mechanisms; thus, we do not suggest prescribing antibiotics
using CF-based dosing regimens, as it can be potentially dangerous for some agents. +: refers to identifying when and in whom long-term
antibiotics should be used to induce clinical stability. §: the ERS Clinical Practice Guidelines [12] state that “In children/adolescents with
bronchiectasis, we suggest the decision to repeat chest CT scans is individualised based on the clinical status and setting. Remarks: Repeat chest
CT scans should be considered to answer a question which will change management.”
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Top 10 research priorities and consensus statements
Full consensus (table 4) was obtained. From these, the consensus statements below (no priority order) were
developed and summarised (further detailed in the supplementary material).
• Identifying risk and protective factors for bronchiectasis
There are currently limited data and evidence for factors important for reversibility and/or prevention of
bronchiectasis [12].
Consensus statement: Intervention studies that potentially reduce and/or prevent bronchiectasis are
required. Examples include novel and/or maternal vaccinations to prevent early and/or severe
childhood pneumonia and long-term azithromycin for recurrent protracted bacterial bronchitis.
Additionally, long-term observational studies that delineate currently unidentified risk and
protective factors for developing bronchiectasis are required.
• Identifying the underlying aetiologies of bronchiectasis
Bronchiectasis has varying aetiologies [4]. The ERS CPG recommended undertaking a minimum panel of
tests to identify underlying causes that may alter treatment approaches [12]. However, an underlying
aetiology often cannot be ascertained. Little new data have been generated recently with recurrent protracted
bacterial bronchitis (>3 episodes within 12 months of initial diagnosis) [13] being an exception. Identifying
the underlying aetiologies of bronchiectasis may lead to new prevention and/or treatment approaches.
Consensus statement: Studies that further define a standard panel for identifying and/or predicting
bronchiectasis are required. Examples include using novel technologies e.g. genomics,
breathnomics and blood/airway gene expression signatures. Additionally, long-term observational
studies to delineate new aetiologies associated with bronchiectasis developing are needed.
• Discovering ways to diagnose bronchiectasis earlier, including ways to increase health practitioner
awareness and to facilitate earlier referrals
TABLE 2 Parent/patient survey: research priorities and themes




Finding ways to prevent bronchiectasis 3.89
Identifying how bronchiectasis develops and continues 3.87
Identifying the cause(s) of bronchiectasis 3.80
Identifying how often and why bronchiectasis occurs in certain groups of people across the
world
3.74
Finding new ways to improve
diagnosis and treatment
Finding ways to diagnose bronchiectasis earlier, such as by local doctors# 3.86
Testing new techniques for managing bronchiectasis in real world environments, such as at
home and community settings (not in the laboratory or in hospitals)
3.86
Finding new medicines to treat bronchiectasis 3.84
Finding new physiotherapy/airway clearance techniques 3.79
Using longer-term antibiotic therapy when a person’s condition is stable¶ 3.71
Developing medicines that can be taken in different ways, such as for inhaled or nebulised 3.67
Improving knowledge and
treatment of exacerbations
Identifying triggers for an exacerbation 3.86
Identifying people at increased risk of poor outcomes or needing urgent treatment for their
bronchiectasis
3.85
Using vaccines to prevent exacerbations 3.78
Exploring the link between getting a cold (for example rhinovirus) and having an exacerbation 3.74
Improving monitoring and how to
identify predictors of disease
progression
Identifying what makes some patients’ bronchiectasis get worse 3.92
Understanding the relationship between bronchiectasis and other medical conditions, e.g.
asthma, “acid” reflux
3.80
Being able to monitor and treat the coughing up of blood 3.77
Having regular lung function testing to help notice changes or increased risk of an exacerbation 3.76
Being able to monitor cough 3.68
#: refers to parent’s/patient’s experience of delayed referral due to lack of awareness of the symptoms of bronchiectasis and dismissing children’s
chronic wet cough; we do not expect primary care doctors to undertake computed tomography scans in young children. ¶: refers to identifying
when and in whom long-term antibiotics should be used to induce clinical stability.
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TABLE 3 Health practitioner survey: research priorities and themes
Theme In children and young people with bronchiectasis (unrelated to cystic fibrosis) Mean
score
Finding new ways to improve
treatment
When and how (antibiotic, dose, regimen, route (intravenous, oral or inhaled/nebulised) and
duration) should pathogens other than Pseudomonas aeruginosa be eradicated, and do
patient outcomes improve afterwards?
4.27
What are the optimal and most cost-effective airway clearance techniques? 4.26
When and how (antibiotic, dose, regimen, route (intravenous, oral or inhaled/nebulised) and
duration) should P. aeruginosa be eradicated, and do patient outcomes improve
afterwards?
4.18
What is the best antibiotic, dose, regimen and duration for long-term oral antibiotic therapy
in patients with bronchiectasis (according to the presence or absence of P. aeruginosa or
other pathogens)?
4.17
What are the indications of oral versus inhaled/nebulised long-term suppressive antibiotic
treatment?
4.14
When should airway clearance techniques be started in patients with bronchiectasis, and how
often should it be done during the stable state and for exacerbations?
4.09
What is the impact of long-term antibiotic therapy on anti-microbial resistance? 4.03
What is the role of different mucoactive agents (e.g. inhaled hypertonic or isotonic saline,
mannitol, oral erdosteine or N-acetyl cysteine)?
4.03
What are the simple, reliable microbiological tests for determining lower airway infection? 3.90
What are the most efficient clinical trial designs and measurable outcomes? 3.83
What are the key factors leading to P. aeruginosa acquisition and infection? 3.78
Which clinical and microbiological factors affect macrolide efficacy? 3.71
What is the role of surgery (segmentectomy, lobectomy or pneumonectomy) and when
should it be undertaken?
3.62
What is the role of long-term inhaled corticosteroids? 3.53
What is the role of non-pharmacological, non-airway clearance technique-based therapeutics,
such as singing exercise, wind instruments and yoga during stable states and acute
exacerbations?
3.45
What is the best model/approach for transferring an adolescent with bronchiectasis to adult
services?
3.42
Finding new ways to improve
diagnosis
What are the baseline investigations to identify underlying aetiologies of bronchiectasis? 3.98
What clinical factors should be present to trigger referring a child for a chest computed
tomography scan to diagnose bronchiectasis?
3.87
Improving knowledge and treatment
of exacerbations
What is the optimal antibiotic therapy (dosage, how many antibiotics, type, oral versus
intravenous versus inhaled/nebulised and length of therapy) for an exacerbation of
bronchiectasis?
4.41
What are the most important factors to prevent acute exacerbations? 4.12
How to define acute exacerbations that require additional treatment? 4.05
What are the causes of an exacerbation of bronchiectasis? 3.84
Which are the best systemic (e.g. blood) or local (e.g. sputum) inflammatory markers for the
diagnosis, management and follow-up for an exacerbation?
3.82
How should the severity of an exacerbation of bronchiectasis be assessed and what is its
impact on long-term outcomes?
3.78
What types of biomarker(s) can be used for predicting bronchiectasis exacerbation? 3.68
Improving prevention and monitoring What are the risk factors and causes of rapid progression of lung disease and poor outcomes
(e.g. hospitalisation, lung transplantation and mortality)?
4.17
How best to prevent development of bronchiectasis? 4.16
Should there be paediatric-focused patient registries? 4.06
What are the best and most pragmatic functional tests (such as carbon monoxide diffusing
capacity, 6-min walk test, lung clearance index, endurance shuttle walk, incremental
exercise tests or accelerometers) as markers for severity of the disease, outcomes and
end-points for the clinic?
4.00
What are the risk or protective factors for lung function decline in patients with
bronchiectasis?
3.91
What are the factors that predict radiographic reversibility (on a high-resolution computed
tomography scan)?
3.84
What is the best approach/score to evaluate radiographic severity? 3.82
What types of specific patient education packages, self-management plans and patient
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Published literature supports the PAG’s experience of long delays in diagnosing bronchiectasis in
children [14, 15]. Earlier diagnosis requires recognition and treatment of chronic cough (predominant
symptom of bronchiectasis [1]), increased patient and health professional awareness, suitable educational
resources and health systems that support early and appropriate referrals to specialists with access to
diagnostic capability. These capabilities include adopting the ERS CPG recommendation of using
multi-detector chest computed tomography (CT) routinely with high-resolution computed tomography
(HRCT) scans rather than HRCT scans alone and employing the paediatric-derived broncho-arterial
ratio to define abnormality [12].
Consensus statement: Implementation science-based studies are needed to increase: 1) health
practitioner awareness and 2) use of guidelines that facilitate earlier bronchiectasis diagnosis and
referrals. We encourage research on novel diagnostic techniques, including those that can reduce
human variability in diagnosis (e.g. artificial intelligence) and/or provide alternate/complementary
methods to current standards relying upon chest CT scans. Additionally, research is required to
identify and promote the early symptoms and signs of underlying bronchiectasis and develop simple
biomarkers to allow local physicians and paediatricians to recognise this disorder promptly and
reduce the risk of irreversible damage to the developing airways of young children.
• Identifying triggers/prevention factors and optimal antibiotic treatment for acute exacerbations
Few data exist on finding triggers of exacerbations [16, 17] with the only trigger studied in CYP with
bronchiectasis being viral-associated infections [18].
While bronchiectasis guidelines recommend antibiotics for respiratory exacerbations in both CYP and
adults, data from a randomised controlled trial (RCT) on antibiotics for non-hospitalised exacerbations in
children [19] suggest that a subset do not require these agents.
TABLE 3 Continued
Theme In children and young people with bronchiectasis (unrelated to cystic fibrosis) Mean
score
Should a severity and prognostic score for children that is useful in clinical practice be
developed?
3.70
What comorbidities are present and how do they influence bronchiectasis severity? 3.59
Is cross-infection important, what are the best strategies and is strict patient segregation
required?
3.59
What types of biomarker(s) can be used to monitor bronchiectasis severity during stable
state, so as to define the subgroup who will benefit from more intensive treatment?
3.58
Can endo-phenotyping predict severity and outcomes in children? 3.54
Understanding mechanisms and
biology of bronchiectasis
Do different aetiologies and/or comorbidities of bronchiectasis predetermine microbiological
characteristics and affect severity, patients’ quality of life and disease progression?
3.92
What is the role of viruses, fungi and anaerobes (as single agents and/or polymicrobial
infections), during both the stable state and exacerbation, and what is their impact upon
patient severity and outcomes?
3.85
Is there an increased rate of primary immune defects (e.g. mannose-binding lectin deficiency,
common variable immunodeficiency, IgM or IgA deficiency, or complement deficiency)?
3.78
What is the incidence and prevalence of different aetiologies of bronchiectasis across the
world?
3.55
What is the relationship between paediatric and adult bronchiectasis? 3.54
What is the importance of host–pathogen–environment interactions? 3.53
What are the molecular and cellular mechanisms and pathobiological pathways of
bronchiectasis development, exacerbations and progression?
3.52
What is the composition and function of the host microbiome, both during the stable state
and exacerbations, and does it impact directly disease severity and progression?
3.48
What are the genetic and epigenetic findings in patients with bronchiectasis compared to
healthy controls, and what is their role in acquisition of specific pathogens and patients’
outcomes?
3.39
What is the best experimental model system of bronchiectasis? 3.24
Other What are the healthcare costs of bronchiectasis management across the world? 3.19
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TABLE 4 Derivation of the top 10 research priorities#
Consensus priorities (parent/patient and
health practitioners) and confirmed
with two parent advisory groups
Parent/patient survey (verbatim from
survey questions)
Health practitioner survey (verbatim from survey
questions)
Theme: Understanding mechanisms and biology of bronchiectasis
Identifying risk and protective factors for
bronchiectasis
Identifying what makes some patients’
bronchiectasis get worse
How best to prevent development of bronchiectasis?
Finding ways to prevent bronchiectasis
Identifying the underlying aetiologies of
bronchiectasis
Identifying the cause(s) of bronchiectasis What are the baseline investigations to identify
underlying aetiologies of bronchiectasis?
Theme: Diagnosis
Discovering ways to diagnose
bronchiectasis earlier, including ways
to increase health practitioner
awareness and to facilitate earlier
referrals
Discovering ways to diagnose
bronchiectasis earlier, such as by local
doctors¶
Theme: Improving knowledge and treatment of exacerbations
Identifying triggers/prevention factors
and optimal antibiotic treatment for
acute exacerbations
Identifying triggers for an exacerbation What are the most important factors at preventing
acute exacerbations?
Exploring the link between getting a cold
(for example rhinovirus) and having an
exacerbation
What is the optimal antibiotic therapy (dosage, how
many antibiotics, type, oral versus intravenous versus
inhaled/nebulised and length of therapy) for an
exacerbation of bronchiectasis?
Using vaccines to prevent exacerbations
Theme: Finding new ways to improve treatment




What are the optimal and most cost-effective airway
clearance techniques?
When should airway clearance techniques be started in
patients with bronchiectasis, and how often should
it be done during the stable state and for
exacerbations?
Defining optimal antibiotic therapy for
eradicating specific pathogens (e.g.
Pseudomonas aeruginosa) and for
suppressing bacteria once chronic
infection is established
Using longer-term antibiotic therapy when
a person’s condition is stable+
When and how (antibiotic, dose, regimen, route
(intravenous, oral or inhaled/nebulised) and
duration) should P. aeruginosa be eradicated, and do
patient outcomes improve afterwards?
When and how (antibiotic, dose, regimen, route
(intravenous, oral or inhaled/nebulised) and
duration) should pathogens other than P. aeruginosa
be eradicated, and do patient outcomes improve
afterwards?
What are the indications of oral versus inhaled/
nebulised long-term suppressive antibiotic
treatment?
What is the best antibiotic, dose, regimen and duration
for long-term oral antibiotic therapy in patients with
bronchiectasis (according to the presence or absence
of P. aeruginosa or other pathogens)?
Finding new medications and/or
techniques for managing
bronchiectasis
Testing new techniques for managing
bronchiectasis in real world
environments, such as at home and
community
What is the role of different mucoactive agents (e.g.
inhaled hypertonic or isotonic saline, mannitol, oral
erdosteine or N-acetyl cysteine)?
Finding new medicines to treat
bronchiectasis
Theme: Improving monitoring and how to identify predictors of disease progression
Identifying lung function tests/indices
that predict outcomes
Having regular lung function testing to
help notice changes or increased risk of
an exacerbation
What are the best and most pragmatic functional tests
(such as carbon monoxide diffusing capacity, 6-min
walk test, lung clearance index, endurance shuttle
walk, incremental exercise tests or accelerometers)
as markers for severity of the disease, outcomes and
end-points for the clinic?
Continued
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Consensus statement: Large prospective studies are needed to identify triggers of respiratory
exacerbations and those at risk of these episodes. It is also important to generate novel data to
differentiate between children with exacerbations requiring antibiotics from those where they are
unnecessary. Such studies should include identifying systemic and/or airway biomarkers that may
predict exacerbation outcomes.
• Finding new and optimal ACTs
Parents/PAG give high value to airway clearance as a therapeutic modality and highlighted the lack of
access to high-quality therapists. Several ACTs are suitable for various developmental/cognitive stages.
Most ACTs are indicated empirically, usually based on the skills of physiotherapists. Since ACTs was the
highest rated aspect affecting the children’s QoL (figure 2a), new and optimal ACTs are needed for both
stable and exacerbations states.
Consensus statement: We advocate multicentre studies of CYP with bronchiectasis to determine the
efficacy of ACTs based on their frequency and utility of various methods. Innovative techniques that
increase the efficacy of ACTs and reduce the time burden on patients and their carers are needed.
• Defining optimal antibiotic therapy for eradicating specific pathogens (e.g. Pseudomonas aeruginosa)
and for suppressing bacteria once chronic infection is established
Although P. aeruginosa is uncommon in CYP with bronchiectasis, it usually signals multi-lobar disease
and/or serious underlying comorbidities [8]. Health practitioners rated highly the importance of eradicating
bacterial pathogens, especially P. aeruginosa, and how this is achieved. Currently, no published paediatric
data exist, while three small studies in adults were limited to P. aeruginosa infections [20–22].
As eradication is standard practice in CYP with CF [23], it is unlikely that placebo-controlled
P. aeruginosa eradication trials will take place. Therefore, studies comparing various eradication regimens
(e.g. oral versus inhaled anti-pseudomonal antibiotics, alone or in combination, or parenteral antibiotics as
single or dual agents, and varying treatment course duration) are required. Trials are also needed to
determine if eradicating other respiratory bacterial pathogens is possible and beneficial.
The ERS CPG recommends oral macrolides for at least 6 months in those with >1 hospitalised or ⩾3
non-hospitalised exacerbations in the previous 12 months [12]. However, there are limited data and substantial
knowledge gaps remain. RCTs are required to identify CYP with bronchiectasis most likely to benefit from
long-term antibiotics (e.g. number of exacerbations/year), as well as to define which antibiotic (e.g. macrolide
TABLE 4 Continued
Consensus priorities (parent/patient and
health practitioners) and confirmed
with two parent advisory groups
Parent/patient survey (verbatim from
survey questions)
Health practitioner survey (verbatim from survey
questions)
Understanding the relationship between
causes and comorbidities of
bronchiectasis with clinical outcomes
To know how bronchiectasis affects other
body parts/organs in addition to the
lung
Do different aetiologies and/or comorbidities of
bronchiectasis predetermine microbiological
characteristics, and affect severity, patients’ quality
of life and disease progression?
To understand the relationship between
bronchiectasis and other medical
conditions e.g. asthma, “acid” reflux
Identifying factors associated with worse
bronchiectasis outcomes
Identifying what makes some patients’
bronchiectasis get worse
What are the risk factors and causes of rapid
progression of lung disease and poor outcomes (e.g.
hospitalisation, lung transplantation and mortality)?
Identifying people at increased risk of
poor outcomes or needing urgent
treatment for their bronchiectasis
What are the risk or protective factors for lung function
decline in patients with bronchiectasis?
#: the list is not in order of priority, i.e. all are considered equal. ¶: refers to parent’s/patient’s experience of delayed referral due to lack of
awareness of the symptoms of bronchiectasis and dismissing children’s chronic wet cough; we do not expect primary care doctors to undertake
computed tomography scans in young children. +: refers to identifying when and in whom long-term antibiotics should be used to induce clinical
stability.
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versus inhaled antibiotics) to prescribe, the optimum duration of treatment, describe how long these beneficial
effects persist and establish the clinical significance of antibiotic-resistant respiratory bacterial pathogens.
Consensus statement: RCTs are needed to identify those benefiting from long-term antibiotics as
well as the optimal antibiotic regimens (including oral or inhaled formulations) and their duration
for eradicating bacterial pathogens (e.g. P. aeruginosa) and reducing exacerbations. Both clinical
and patient-focused benefits and harm should be identified in these trials. Studies on the safety and
efficacy of inhaled antibiotics in CYP and determining risk factors and clinical impact of
anti-microbial resistance are also required.
• Finding new medications and/or techniques for managing bronchiectasis
There are still no licensed long-term therapies available for bronchiectasis [4, 24]. Current treatments are
mostly extrapolated from the CF literature, sometimes with adverse results when later subjected to
high-quality RCTs [25].
Consensus statement: Investment in developing and/or assessing new therapeutics that can improve
the lives of CYP with bronchiectasis are needed. This includes investment from both commercial
and research funding bodies to accelerate the conduct of basic scientific studies and multicentre
RCTs to allow the identification and licensing of beneficial therapeutic agents.
• Identifying lung function tests/indices that predict outcomes
Tools that can monitor disease and predict outcomes are important for managing chronic diseases. Such
prognostic/severity tools have been developed in adults with bronchiectasis but are not applicable in CYP [1].
Consensus statement: We require tools and indices that can be used to effectively monitor disease
severity and predict outcomes for CYP with bronchiectasis. Longitudinal studies should be
conducted in CYP with bronchiectasis to monitor lung function and other indices to identify specific
monitoring parameters that can predict outcomes. The impact of reduced lung function upon
respiratory and general health should be considered.
• Understanding the relationship between causes and comorbidities of bronchiectasis with clinical
outcomes
Bronchiectasis is the “final common pathway” of a pathobiological process involving impaired airway
clearance, chronic lower airway infection and inflammation. The various aetiologies and comorbidities (e.g.
concurrent asthma, gastro-oesophageal disease, airway malacia) potentially represent paediatric phenotypes
and “treatable traits” [1]. However, limited data on paediatric bronchiectasis phenotypes or treatable traits
exist.
Consensus statement: Well-characterised large cohorts of CYP with bronchiectasis that advance the
concept of phenotypes and “treatable traits” are required. This includes utilising mathematical
modelling methods and multiparametric immunophenotyping.
• Identifying factors associated with worse bronchiectasis outcomes
Bronchiectasis, described previously as irreversible bronchial dilatation [26], is now defined as abnormal
bronchial dilatation on chest CT scans with the phenotype of chronic or recurrent wet/productive cough
and pulmonary exacerbations [1, 4]. Outcomes of bronchiectasis are varied, and mild radiographic
bronchiectasis in children is potentially reversible when optimal treatment commences early in the disease [1].
Identifying factors influencing illness progression are important as these represent potential intervention
points, i.e. secondary prevention, and may lead to new pharmacological agents.
Consensus statement: Long-term observational studies in large cohorts across multiple settings to
further delineate factors influencing outcomes of CYP with bronchiectasis are required. These
include genetic and environmental factors that predispose some patients to chronic infections (e.g.
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with P. aeruginosa) and/or frequent exacerbations. Studies with innovative treatment protocols
based on patient phenotypes are also needed.
Discussion
We present the first document on the clinical needs of CYP with bronchiectasis and their carers, and
highlight issues that most affect their QoL. Additionally, the 10 consensus research priorities outlined in
our roadmap were developed conjointly by parents/patients, patient advocates with a multi-disciplinary
panel of expert clinicians and clinician-researchers in the field. These topics were across four themes:
understanding mechanisms and biology; diagnosis; improving knowledge and treatment of exacerbations;
and finding new ways to improve treatment.
Bronchiectasis remains relatively under-researched and under-serviced [27], where the unmet needs of
people with bronchiectasis are huge and there are relatively few RCTs [1, 4, 28]. A focus on CYP is
advantageous as mild radiographic bronchiectasis is potentially reversible if treated early, thereby avoiding
the later progressive decline in lung function while prevention remains the ultimate goal [1]. Novel and
concerted approaches are required, and this document highlights both clinical gaps and research priorities.
Using these priorities should lead to better clinical services and research questions, thereby improving the
lives of CYP with bronchiectasis and their families. Indeed, data from several different longitudinal
paediatric cohorts demonstrate lung function in bronchiectasis can be improved [29–33] and remain within
the normal range over the long term [34]. Furthermore, while still contentious, recent prospective data
suggest that catch-up lung function in children can occur, leading to normal lung function in adulthood
[35]. Although such observations need further confirmation, as lung trajectories were once thought to
remain unchanged for life, this is particularly important as low spirometric lung function impairment even
in the clinically normal range, is an independent prognostic marker of respiratory and cardiovascular
disease mortality across a broad range of socioeconomic backgrounds and environmental settings [36–38].
The document has several strengths. Firstly, we engaged parents and patients (with ELF support) so as to
bring relevance and increase the value of treatment by ensuring that care is responsive to societal changes
and public expectations, elements which had been missing in CYP with bronchiectasis. Such data are
essential for guiding research and clinical efforts to improve the lives of people with bronchiectasis.
Secondly, the surveys were international, across high- and low–middle-income countries. Thirdly, the work
accompanied the first international CPG on managing children and adolescents with bronchiectasis [12].
The CPG [12] provided up-to-date data from their systematic reviews on existing knowledge gaps in
paediatric bronchiectasis.
Nevertheless, there are important limitations to consider. The proportion of parents/patients responding to
the survey is unknown and some responses were incomplete. The survey that required access to the
web-based technology and the internet (i.e. we did not have a paper-based option) may have limited
participation in some sections of the community. This work was supported by an ERS taskforce, with
limited reach to Asia, Africa and the Americas. Also, only ∼20% of members of the paediatrics assembly
of the ERS responded, but this is not unexpected as not all assembly members are clinicians and/or
manage CYP with bronchiectasis. Nevertheless, it is possible that the views of parents/patients and health
practitioners may not be representative of the broader community of those with bronchiectasis and their
families or the health practitioners caring for such patients. Additional points are raised in the
supplementary material. Finally, we could not ascertain how views might change with the age of the child;
it is possible that parents of a newly diagnosed child may have different views (e.g. focusing on early
diagnosis) compared to a young person with established disease (e.g. more concerned about the detection
and management of pulmonary exacerbations).
Conclusions
This document highlights the clinical needs of CYP with bronchiectasis and their carers, in addition to
providing an international roadmap for research priorities as a consensus statement. The roadmap was
developed by parents/patients, patient advocates and expert clinicians in the field. It should act as a
valuable resource for health services, grant funding bodies, clinicians and researchers to stimulate better
health service and research for improving the lives and outcomes of CYP with bronchiectasis and their
families. In so doing, it will not only address this relatively under-researched and under-serviced [27]
chronic disorder, but it will also lead to improved lung health for the patients as adults by reversing the
disease and/or curtailing its high illness burden.
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